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Cardiac muscle performance can be determined by factors intrinsic to each cardiac muscle cell,
such as protein isoform expression. One protein whose expression plays a major role in deter-
mining cardiac performance is myosin. Myosin is the heart’s molecular motor which transduces
the chemical energy from ATP hydrolysis into the mechanical energy of each heartbeat. Alter-
ations of myosin isoform expression are routinely associated with acquired and inherited cases
of cardiomyopathy. For example, human heart failure is consistently associated with increased
expression of a slow myosin motor isoform and a concomitant decreased expression of the heart’s
fast myosin motor isoform. Further, mutations of the cardiac myosin gene are the most common
cause of inherited hypertrophic cardiomyopathy. Transgenic animal studies have provided insight
into cardiac functional effects caused by myosin isoform gene switching (fast-to-slow myosin or
slow-to-fast myosin) or by expression of a disease-related mutant motor. More direct structure–
function analysis using acute gene transfer of myosin motors provides evidence that the inotropic
state of cardiac muscle can be affected by motor protein isoform shifting independent of intracel-
lular calcium handling. Because most therapies for the diseased heart target intracellular calcium
handling, acute gene transfer of cardiac molecular motors to modulate heart performance offers a
novel therapeutic strategy for the compromised heart. Although the development of safe vectors for
therapeutic myosin gene delivery are in their infancy, studies focused on acute genetic engineering
of the heart’s molecular motor will provide a foundation for therapeutic vector development and
insight into mechanisms that contribute to cardiomyopathy.
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Introduction
Oxygen and nutrient-rich blood is pumped to the
body’s tissues with each heartbeat. The force and pres-
sure development of each heartbeat are due to the
contraction and shortening of cardiac muscle. At the
molecular level cardiac muscle contraction involves
complex dynamic interactions between calcium and
the myofilament proteins. Cardiac muscle force gener-
ation and shortening are initiated by calcium released
from intracellular stores of the sarcoplasmic reticulum
(SR) and executed by the activity of molecular mo-
tors within the myofilaments. A popular perspective is
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that the level of force (or pressure) generation of car-
diac muscle is determined primarily by the amount
of calcium released from the SR and delivered to the
myofilaments. However, mounting evidence suggests
that cardiac muscle performance can also be altered
independent of the calcium signal by the activity of
the heart’s molecular motor. In fact, a recent review
article1 has proposed a dominant role for molecular
motors in the intrinsic regulation of cardiac perfor-
mance.
Heart failure is a major health problem, affecting
over 5 million people in the United States, and the
numbers continue to grow. In cases of heart failure,
cardiac performance is diminished and the pumping
action of the heart is poor. As a result, the heart is
unable to supply a sufficient amount of oxygenated
and nutrient-rich blood to the tissues and organs that
demand it. Common symptoms of heart failure in-
clude dyspnea, exercise intolerance, and edema. Cur-
rent therapies manage the symptoms of heart failure
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and surgical intervention or cardiac transplantation is
ultimately necessary. The development of novel ther-
apies for heart failure is clearly necessary, and some
investigators have predicted a shift in emphasis toward
the development of gene-based therapy.2 One closely
related pair of genes consistently associated with heart
failure is the one that encodes the heart’s molecular
motors.3–5
The importance of the heart’s molecular motor,
myosin, in the regulation of cardiac performance has
been underscored in the past two decades. Since the
first discovery that a myosin gene missense muta-
tion can cause inherited hypertrophic cardiomyopathy
(HCM)6 nearly 200 other disease-associated myosin
mutations have been identified. Further, myosin
missense mutations have also been implicated in other
inherited cardiovascular diseases, including dilated
cardiomyopathy (DCM),7,8 and in skeletal muscle my-
opathies.9 Since the cardiac phenotype of inherited
cardiomyopathies can be similar to the phenotype of
acquired heart failure, it is likely that alterations of
myosin function contribute to the pathogenesis of more
common forms of heart failure. The clinical impor-
tance of cardiac myosin makes it a good target for
gene transfer experiments using viral vectors to study
the molecular mechanisms that contribute to heart fail-
ure and for the development of novel gene-based ther-
apies.
Molecular Motors: Cardiac Myosin
Isoforms
Cardiac myosin belongs to the myosin II family of
conventional myosins and is the molecular motor that
drives myocardial contraction. Cardiac myosin is the
most abundant protein within cardiac muscle and is
the primary consumer of cellular energy, in the form of
ATP. Muscular contraction is due primarily to cyclical
interactions between interdigitating myosin and actin
filaments. Myosin is an asymmetric molecule made up
of two myosin heavy chains (MyHC) and two pairs of
myosin light chains. The crystal structure of myosin
has been solved10 and at its N terminus MyHC has a
globular head domain which contains both an actin-
binding site and an ATP binding and hydrolysis site
(FIG. 1A). At its C terminus MyHC contains a rod do-
main made up of an α-helical tail that interacts with the
α-helical tail of neighboring MyHC molecules to form
the bipolar thick-filament backbone. Thus, in addition
to hydrolyzing ATP as the heart’s molecular motor,
the MyHC also contributes to the structure of cardiac
muscle. Two structurally and functionally distinct iso-
forms of myosin are differentially expressed in cardiac
muscle, namely, α- and β-MyHC isoforms (FIG. 1A).
These isoforms can form hetero- and homodimers and
these dimers have been separated electrophoretically
and are referred to as myosin V1 (α-α homodimer),
V2 (α-β heterodimer), and V3 (β-β homodimer).11,12
The α- and β-myosin genes, MYH6 and MYH7, re-
spectively, extend over 51 kb on chromosome 14 in
humans13 and chromosome 11 in mouse separated
by 4 kb of sequence between them.13 Transcription
of each gene is independently controlled, but coor-
dinately regulated,14 and changes throughout mam-
malian development. The V3 (β-β homodimer) myosin
isoform is predominantly expressed during early devel-
opment in the ventricles of all mammals and remains
the predominant isoform throughout the lifetime of hu-
mans and larger mammals. The V1 (α-α homodimer)
isoform, on the other hand, predominates soon after
birth in most small mammals and is the predominant
isoform throughout the lifetime of mice and rats.15
Despite sharing >90% amino acid homology,
each molecular motor isoform functions in a distinct
manner. For example, biochemical experiments have
demonstrated that β-MyHC hydrolyzes ATP ∼3–7
times slower than α-MyHC,16,17 the “fast” motor in
the heart. Using the in vitro motility assay, where actin
propulsion by single myosin motors is measured, it has
been demonstrated that α-MyHC propels actin fila-
ments 2–3 times faster than β-MyHC.17,18 These bio-
chemical functional differences between the isoforms
do not manifest as differences in force-generating ca-
pacity between the two isoforms. Using the laser trap
assay, where the amount of isometric force produced
by a single myosin molecule is measured, it has been
demonstrated that α- and β-MyHC generate identi-
cal amounts of force, displace actin by the same ex-
tent, and only differ in their kinetics of ATP hydrol-
ysis product release.19 Although differences in peak
twitch tension are not apparent, the energetic econ-
omy and tension-time integral for preparations con-
taining predominantly V1 myosin are less than that
of preparations with predominantly V3 myosin.20,21
These kinetic differences in the myosin molecular mo-
tor isoforms manifest functionally as differences in
the kinetics of force and power development in the
context of single cardiac myocytes,22 cardiac muscle
strips, and whole heart function.23 FIGURE 1B, for ex-
ample, demonstrates that the power output of single
cardiac myocytes24 is much lower in cardiac myocytes
that exclusively express the β-MyHC isoform com-
pared to cardiac myocytes that only express the faster
α-MyHC molecular motor isoform. Because maxi-
mum force production is not different between the
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FIGURE 1. (A) Schematic representation of the cardiac MyHC molecule. Cardiac myosin is made
up of a globular head domain and an α-helical rod domain. Two distinct myosin isoforms are expressed
in the heart: α- and β-MyHC. (B) Cardiac myosin isoforms determine the power output of single cardiac
muscle cells (reproduced from Herron et al. 24 with permission). (C) Myofilament calcium sensitivity is
reduced in cardiac myocytes that express predominantly β-MyHC.
isoforms, loaded shortening velocities (myocyte short-
ening against a clamped load as the heart does with
each stroke) are faster in cardiac myocytes that express
the faster α-MyHC molecular motor. It has also been
reported that cardiac myofilament responsiveness to
calcium is depressed and the force–calcium relation-
ship is shifted to the right in cardiac myocytes express-
ing the slower β-MyHC isoform25 (FIG. 1C). These ef-
fects of myosin isoform switching are also apparent
at the level of the whole working heart23,26 (FIG. 2).
Collectively, the literature supports a role for myosin




Expression of the slow β-MyHC motor increases
relative to α-MyHC in rodent models of cardiovascu-
lar disease, including diabetes,27 hypothyroidism,22,25
cardiac hypertrophy,28 and in aging.29 In these in-
stances the total amount of myosin remains un-
changed, but the relative expression of each isoform
changes. In rat models of cardiovascular disease, for ex-
ample, the rat cardiac ventricle transforms and expres-
sion of the α-MyHC isoform is replaced by expression
of the slower β-MyHC motor.29,30 Since this switch
of myosin isoform expression occurs in a plethora of
models of heart disease, increased expression of the
β-MyHC motor expression is generally accepted as a
molecular biomarker of cardiac disease in rodents.
Alterations of cardiac MyHC isoform expression
may play a role in the pathogenesis of human heart
failure as well. The “normal” human cardiac ventri-
cles express predominantly β-MyHC (85–90% of total
myosin) and a small amount of the faster α-MyHC
(10–15% of total myosin) motor.4 The failing human
heart is consistently associated with a loss of α-MyHC
and exclusive expression of the slow β-MyHC motor.
Patients undergoing successful treatment of heart fail-
ure with pharmacologic or surgical interventions have
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FIGURE 2. Power output of the whole working heart is reduced as the relative expression of β-MyHC
increases. (From Korte et al.26 Reproduced by permission).
been shown to develop upregulation of levels of α-
MyHC.31–33 These data suggest that levels of α-MyHC
serve at the least as a surrogate marker for cardiac
function in heart failure, but this hypothesis has been
difficult to test directly. In animal models, even a small
increase in expression of α-MyHC results in an increase
in power output by the heart.34 In a rabbit model of in-
duced cardiomyopathy, overexpression of an α-MyHC
transgene was found to be protective.35 Also, in an-
other transgenic model, expression of β-MyHC, with
concomitant downregulation of α-MyHC, was found
to have a detrimental effect on mice that were placed
under cardiovascular stress.36 Taken together, the evi-
dence suggests that acute upregulation of α-MyHC ex-
pression may lead to improved cardiac function, while
increases in β-MyHC expression may be detrimental
to cardiac performance. Study of the direct effects of
increased fast α-MyHC motor expression will require
the use of acute gene transfer of MYH6 (the gene that
encodes α-MyHC) to failing cardiac myocytes in vitro
and to failing hearts in vivo.
Strategies that have been employed to investigate
the functional significance of myosin isoform switch-
ing have inherent limitations. The most commonly
used model has been the rodent hypothyroid animal
model. Thyroid hormone is a potent inducer of α-
MyHC expression and in the absence of thyroid hor-
mone, by thyroidectomy or propyl-thio-uracil (PTU)
treatment, there is a well documented reduction of
α-MyHC expression accompanied by an increase of
β-MyHC expression.14,37 Studies using hypothyroid
rodents have provided evidence that increased β-
MyHC expression depresses contractile function of
single cardiac myocytes24,25,34,38 and in the whole
heart.23,39 However, a key limitation of the hypothy-
roid model is that in concert with alterations in the
MyHC isoform profile, the expression of key calcium
handling proteins, including the SR Ca2+-ATPase
(SERCA2a), are also affected.40,41 Thus, interpretation
of functional data is confounded because SERCA2a
activity itself is well known to markedly affect car-
diac performance.42–44 To address this confounding
issue, which is attributed to altered calcium han-
dling, the permeabilized (skinned) myocyte prepara-
tion, a preparation that eliminates any contribution
of calcium-handling proteins (like SERCA2a) to my-
ocyte functional studies, has been enlisted.24,25 These
studies have demonstrated that mechanical properties
of single myocytes (e.g., power output and unloaded
shortening velocity) are attenuated by increased rela-
tive expression of β-MyHC. While these studies pro-
vided important information about the contribution
of myosin isoforms to myofilament function, they do
not address the role of myosin isoform switching in the
more physiologically relevant setting of the electrically
stimulated intact cardiac muscle cell where excitation–
contraction coupling mechanisms are intact and fully
functional.
Chronic transgenic animal models have also been
used to manipulate MyHC isoform expression in the
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mammalian heart in vivo.35,36,45 Under baseline con-
ditions, the near full replacement of α-MyHC with β-
MyHC in the hearts of transgenic mice had no detected
effects on echocardiography-derived shortening frac-
tion, an in vivo measure of systolic function.36 Isolated
permeabilized muscle preparations from these mice,
however, did show adverse effects on contractile per-
formance at baseline. It is possible that chronic forced
genetic transition from α-MyHC to β-MyHC through-
out the development of these animals may have caused
other adaptations in the mouse heart to compensate
for effects of β-MyHC expression in vivo. This is con-
ceivable, considering that these transgenic mice would
have sustained nearly 150 million contractile cycles
in vivo prior to cardiac performance assessment in adult
mice. In transgenic animal models, therefore, it may
be difficult to distinguish primary effects caused by
forced β-MyHC expression from secondary compen-
satory changes that may occur throughout the develop-
ment and lifetime of a transgenic animal.46 The utiliza-
tion and development of acute gene transfer of myosin
molecular motors circumvents many of the complica-
tion(s) posed by secondary compensatory alterations of
protein expression that may have altered or masked a
direct effect of MyHC isoform switching on cardiac
performance.
Myosin Isoform Switching: Acute
Gene Transfer
We recently used acute genetic engineering to study
the direct effect of increased relative β-MyHC ex-
pression on single membrane intact cardiac myocyte
function.47 Experimentally we designed and gener-
ated a recombinant adenovirus, AdMYH7, to express
the full-length human MYH7 (full-length β-MyHC
molecule) gene in α-MyHC-dominant rat myocytes
in vitro. The efficiency of gene transfer was ∼100%
and stoichiometric replacement of the endogenous α-
MyHC motor with the full length human β-MyHC
motor was shown by Western blot analysis. Proper
sarcomeric incorporation of virally directed β-MyHC
expression was detected in the A-band of the sar-
comere by using indirect immunofluorescence and
high-resolution confocal imaging. Functional effects
of β-MyHC gene transfer were determined in elec-
trically paced myocytes by measuring changes in sar-
comere spacing and intracellular calcium transients
using fura-2. β-MyHC gene transfer attenuated my-
ocyte contractility just 1 day after gene transfer (FIG. 3),
when β-MyHC accounted for just 18% of the total
myosin (FIG. 3). This functional effect was transgene
dose-dependent as the effect on contraction ampli-
tude was greater on day 2, when β-MyHC accounted
for ∼40% of the total myosin. The amplitude of the
electrically stimulated intracellular calcium transient,
however, was not affected by β-MyHC expression.
This study demonstrated for the first time that in-
creased expression of the heart’s slow β-MyHC molec-
ular motor can have calcium-independent negative in-
otropic effects on single cardiac myocyte contractil-
ity. Thus, in addition to being a common molecular
marker for heart failure, increased β-MyHC expres-
sion can directly contribute to cardiac dysfunction.
Acute gene transfer of molecular motors in cardiac
muscle offers a novel means of calcium independent
inotropy.
Cardiac Myosin and Inherited
Cardiomyopathies
Inherited cardiomyopathy can be caused by muta-
tions of sarcomere proteins. The one most commonly
affected sarcomeric protein in familial cardiomyopa-
thy is β-MyHC. Mutations of the MYH7 gene, the
gene that encodes β-MyHC, have been associated
with both HCM and DCM. Although the human
heart expresses predominantly β-MyHC, mutations of
MYH6, the gene that encodes α-MyHC, have recently
been reported to also cause either HCM or DCM.8
The clinical importance of MYH7 mutations is un-
derscored by the finding that MYH7 mutations have
also been linked to skeletal muscle myopathies, includ-
ing Laing distal myopathy,9 myosin storage myopa-
thy,48 and hyaline body myopathy.49 In fact, a report
from the American Heart Association has suggested
that for cardiovascular genetic counseling, genetic
screening should start with examination of the MYH7
gene.50
The first HCM-causing myosin mutation was
discovered in the motor domain of the β-MyHC
molecule.6 This missense mutation results in an
arginine-to-glutamine substitution at position 403
(R403Q), which is located in the actin-binding inter-
face of the N-terminal globular head.51 This mutation
results in the loss of a positively charged amino acid
residue in the actin-binding site. All affected mem-
bers of this large kindred were heterozygous for the
R403Q mutation, and unaffected family members did
not carry this mutation. The R403Q mutation is asso-
ciated with early onset of symptoms and a high mortal-
ity rate, with an average life span of 30–35 years.52,53
Since the discovery of this myosin mutation, much
effort has been devoted to determining how it affects
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FIGURE 3. (A) Gene transfer of the slow β-MyHC motor directly attenuates cardiac myocyte contrac-
tility independent of the intracellular calcium transient.47 (B) Increasing relative β-MyHC expression by
acute gene transfer attenuates contractility in a dose-dependent manner. SL = sarcomere length.
myosin motor function and triggers cardiomyopathy,
but the issue remains unresolved as some studies have
indicated that motor function is impaired,54–57 while
others suggest a gain of function for the myosin mo-
tor.58–61 The links between mutated myosin (R403Q)
function and cardiac hypertrophy are unclear, though
some studies have suggested a mechanism involving al-
tered calcium homeostasis.62–64 The role of calcium in
the pathogenesis initiated by R403Q myosin is unclear
as it has been reported that transgenic animals ex-
pressing R403Q have elevated calcium levels,63 while
other reports suggest depressed calcium levels in heart
cells from these animals.62,64 One limitation of these
elegant studies is that the R403Q mutation was stud-
ied in the context of the mouse α-MyHC molecule
(MYH6 gene), while the disease-causing mutation in
humans occurs in the context of the MYH7 gene (β-
MyHC molecule). As outlined above, α- and β-MyHC
are structurally and functionally distinct, thus making it
conceivable that a point mutation in one molecule may
not affect the other in the same way. A transgenic rab-
bit, whose myosin isoform expression profile is similar
to that of humans, has been developed which expresses
the R403Q mutant myosin in the context of the human
MYH7 gene.65 This model recapitulates much of the
phenotype observed in humans (e.g., fibrosis, cardiac
hypertrophy, whole-organ dysfunction), but the acute
effect of this mutant myosin on cardiac performance
(single-cell contractility and calcium homeostasis) has
not been studied in this model.
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Acute Gene Transfer of HCM Mutant
Myosin
Two studies from different laboratories have used
acute gene transfer technology to study the effect of the
HCM disease-causing R403Q mutant myosin on car-
diac tissue. In 1995, Marian et al.66 used a replication-
deficient recombinant adenoviral construct to deliver
wild-type and mutated (R403Q) human β-MyHC to
feline cardiac myocyte in vitro. The advantage of this
approach is that the feline species is known to develop
HCM with a phenotype identical to that in humans
and that the investigators generated this mutant myosin
in the context of the bona fide disease-causing gene
(MYH7). The efficiency of in vitro gene transfer was re-
portedly high (>95%), and the mutant myosin caused
sarcomere disruption 120 hours after gene transfer.
While this study indicated that disruption of sarcomere
assembly and myofibrillar organization due to mutant
β-MyHC is a primary defect in HCM, it did not as-
sess the acute functional effect of this mutant myosin
on cardiac performance (i.e., single-cell contractility or
intracellular calcium homeostasis.).
In 2003, Wang et al.67 investigated the functional
impact of mutant myosin on cardiac myofibril orga-
nization and myosin motor activity. Using embryonic
chicken myosin fused to a GFP reporter, Wang et al.
found that expression of the R403Q mutant myosin ac-
celerated actin filament sliding, but decreased myosin’s
affinity for actin in an in vitro motility assay. This is
consistent with previous reports that suggest augmen-
tation of myosin function due to the R403Q muta-
tion.58–61 Insight from this study, however, is limited
since the myosin used was tagged with GFP, a fluo-
rescent molecule that can have direct effects on ac-
tomyosin interactions.68 Further, this study performed
acute gene transfer of mutant myosin in chicken em-
bryonic cardiac myocytes and in a mouse myogenic
cell line (C2C12) and not in adult mammalian cardiac
myocytes. The direct effects of mutant myosin on adult
cardiac myocyte contractility and calcium homeostasis
using acute gene transfer technology are largely unex-
plored. Determination of the acute effects of mutant
myosins on adult myocyte function will provide impor-
tant insight into molecular triggers that initiate and
contribute to cardiac disease.
Summary
Cardiac molecular motors are important regulators
of cardiac performance. Cardiac muscle contraction is
initiated by calcium binding to and activating the thin
filament, thus promoting molecular motor (myosin)
activity and force generation. While the amount of
force generation can be graded with calcium, myocyte
contractility can also be altered by the motor protein
isoform expression profile. Experimentally, acute gene
transfer of the slow β-MyHC molecular motor provides
a means of calcium-independent negative inotropy in
single cardiac myocytes. Acute gene transfer of the fast
α-MyHC molecular motor may provide a means of
calcium-independent positive inotropy, though this re-
mains to be tested in the laboratory. While acute gene
transfer of molecular motors is in its infancy, future
research aimed at using myosin gene transfer as a ther-
apeutic agent for the failing heart will require devel-
opment of safe and effective vectors for delivery of the
myosin gene (∼6 kb) to the heart in vivo. The study of
acute functional effects of disease-causing myosin mu-
tations that trigger cardiomyopathy will provide mech-
anistic insight into the molecular mechanisms that ini-
tiate heart disease.
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